1.5 Abstract in rivista

1.5 Abstract in rivista: [2295] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 641 a 660 di 2.295

Dipeptidyl peptidase 4 inhibitor sitagliptin reduces oxidative stress, endothelial dysfunction and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

2016 Urbanek, K; Cappetta, D; Piegari, Elena; Esposito, G; Russo, R; Ciuffreda, Lp; Rivellino, A; Berrino, Liberato; Rossi, Francesco; DE ANGELIS, Antonella

Diurnal time course of sleepiness in Italian junior and high school students

2016 Cerasuolo, M; Arzilli, C; Conte, F; Giganti, F; Ficca, Gianluca

A methodology to awake citizens' awareness on the effects of leisure noise

2017 Maffei, Luigi; Masullo, Massimiliano; Ciaburro, Giuseppe; D'Onofrio, L.

A Unique Myopathy Syndrome in a Patient Disclosing Clinical, Laboratory, and Genetic Findings of Late-Onset Pompe Disease, Together with a Lack of Dysferlin on Muscle Biopsy

2015 Sampaolo, Simone; Lombardi, Luca; Pascarella, Angelo; Picillo, Esther; Farina, Olimpia; Esposito, Teresa; Politano, Luisa; DI IORIO, Giuseppe

18. Imapired excerise performance in systemic sclerosis. Clinical correlations

2008 Valentini, G.; Santoriello, C.; Cuomo, Giovanna; Polverino, F.; Ruocco, L.; Polverino, M. .

[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes

2009 Abignano, G.; Iudici, M.; Petrillo, A.; Cuomo, Giovanna; Valentini, Gabriele

TWENTYFOUR-MONTH AZATHIOPRINE AS MAINTENANCE THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE TREATED WITH LOW DOSE CYCLOPHOSPHAMIDE PULSE THERAPY

2009 Abignano, G.; Cuomo, Giovanna; Iudici, M.; Petrillo, A.; Valentini, G.

[FRI0311] CORRELATIONS BETWEEN CLINICAL FEATURES OF154 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND SHORT FORM36 (SF36) SCORES G. Cuomo, M. Iudici, G. Abignano, A. Petrillo, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Background: The quality of life is reduced in patients with systemic sclerosis (SSc) as evaluated by both disease specific (HAQ-DI; SHAQ) or generic questionnaires. The correlations between SF-36 scores and some disease features have not yet been explored. Objectives: To evaluate the relationships between health values as evaluated by SF-36 and clinical features in SSc patients. Methods: From 9/01/07 to 8/31/08 154 consecutive SSc patients (144 females; 10 males); aged from 20–82 years (median age 54), with disease duration from 1-47 years (median 10,5 years); attending the outpatient clinic of the Rheumatology Unit of Second University of Naples, were enrolled in the study. The scores of the eight areas of SF-36 General Health: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social function (SF), Role Emotional (RE) and Mental Health (MH), were evaluated in the range of 0–100, the higher values reflecting a better Quality of life (Qol). In addition two global series i.e. the Physical Component Summary Score (PCS) and the Mental Component Summary Score (MCS) were calculated. The patients were also investigated for disease subset (limited or diffuse); skin involvement by the modified Rodnan skin score; disability by HAQ-DI; disease activity by European Activity Index, and disease severity by Medsger severity scale. Results: SF36 score did not differ between the 31 patients with diffuse vs the 123 with limited disease All the items of SF36 were significantly correlated to activity Index (Rho from –0.28 to -0.32: p<0.0001) and HAQ-DI (Rho from -0.38 to -0.82: p<0.0001). GH resulted to correlate with mRss (Rho -0.17; p<0.05) The significant correlations between each item of the Medsger's severity scale and each item of SF36 are reported in table. PF RP BP GH VT SF RE MH PCS/MCS Sev_Gen (Rho) – – – – – – – – –/– Sev_Vasc(Rho) – – – – – – – – –/– Sev_Skin (Rho) – – – – – – – – –/– Sev_Joint (Rho) – – – -0.18* – – – – -0.21/– Sev_muscle (Rho) -0.25 – – -0.16* -0.18* -0.22* – -0.20* -0.20/– Sev_GI (Rho) -0.20 – – -0.22 – – – – –/– Sev_lung (Rho) -0.28* – – -0.23** -0.17* -0.23 -0.22 – -0.19/– Sev_Heart (Rho) – – -0.22 – – – – – -0.21/– Sev_kidney (Rho) – – – – – – – – – p<0.05; p<0.001; *p<0.0001. Conclusion: The present study, confirms that the Health Value, as evaluated by SF36, is diminished in SSc. Our study point out a previously univestigated correlation between SF-36 scores and disease activity. Disclosure of Interest: NONE declared Ann Rheum Dis 2009;68(Suppl3):459 Session: Scleroderma, myositis and related syndromes

2009 Cuomo, Giovanna; Iudici, M.; Abignano, G.; Petrillo, A.; Valentini, G.

MYCOPHENOLATE MOFETIL IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS

2009 Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G. .

AUTOANTIBODIES AND CLINICAL FEATURES CAN PREDICT EVOLUTION IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE (MCTD)

2011 Cappelli, S.; Bellando Randone, S.; Martinovic, D.; Tamas, M. M.; Pasalic, K.; Allanore, Y.; Mosca, M.; Talarico, R.; Opris, D.; Kiss, C.; Tausche, A. K.; Cardarelli, S.; Riccieri, V.; Koneva, O.; Cuomo, Giovanna; Becker, M. O.; Sulli, A.; Guiducci, S.; Radic, M.; Bombardieri, S.; Aringer, M.; Cozzi, F.; Valesini, G.; Ananieva, L.; Valentini, G.; Riemekasten, G.; Cutolo, M.; Ionescu, R.; Czirják, L.; Damjanov, N.; Rednic, S.; Matucci Cerinic, M.

ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC). ULTRASONOGRAPHIC FEATURES OF HAND JOINTS

2009 Cuomo, Giovanna; Zappia, M.; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G.

THE ROLE OF HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) IN PREDICTING SURVIVAL IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC)

2011 Iudici, M.; Cuomo, Giovanna; D'Abrosca, V.; Irace, R.; Valentini, G.

COURSE OF HBV INFECTION IN PATIENTS UNDERGOING TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)

2011 Urraro, T.; Cuomo, Giovanna; Valentini, G.

HYPOCOMPLEMENTEMIA IN SYSTEMIC SCLEROSIS (SSC)

2008 Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Valentini, G.

CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS

2007 Vettori, Serena; Abbadessa, Salvatore; Chiarolanza, I.; Ruocco, L.; Cuomo, Giovanna; Maresca, L.; Leonardo, G.; Valentini, G.

ELF TEST: A PROMISING SURROGATE OUTCOME MEASURE IN SYSTEMIC SCLEROSIS

2011 G., Abignano; Cuomo, Giovanna; Buch, M.; Rosenberg, W. M.; Valentini, G.; Emery, P.

[THU0309] CLINICAL MANIFESTATIONS IN LATE VS EARLY –ONSET SYSTEMIC SCLEROSIS (SSC) G. Cuomo, M. Iudici, G. Abignano, G. Valentini. Second Universty of Naples, Rheumatology Unit, Naples, Italy Background: Differences have been so far pointed out in the clinical manifestations and disease course in patients with a number of autoimmune rheumatic diseases and different age at onset (1-3). Objectives: To investigate the occurrence of differences between early and late onset SSc. Methods: 260 SSc patients (233 females) with a median age at the onset of the disease of 40.5 years (range 8-74) were consecutively admitted to a tertiary centre from November 1st 2000 to October 31st 2008. They were divided into 2 groups: early onset (<40.5 years) and late onset (≥40.5 years). Differences in each of the epidemiological, clinical and serological aspects collected in all the patients at admission were analysed. Results: Table 1 lists the significant differences detected between the 2 groups. Early onset patients were found to have a longer disease duration at presentation, a higher prevalence of anti-Scl70 positivity and a higher prevalence of scleroderma renal crisis; a lower prevalence of antinucleolar antibody positivity; a lower percentage of pulmonary hypertension; a lower HAQ-DI and a lower prevalence of heart involvement. No difference was detected in clinical subset distribution. Late onset (138) Early onset (122) p Disease duration mean (sd) 6 (6) 10 (10) 0.003 Range (median) 0.5-26 (5) 0.5-45 (6) Serological subset Scl70 43 54 0.04 Nucleolar 9 23 0.004 PAPs ≥40mmHG (echocardiography) 14/124 3/119 0.01 HAQ-DI mean (sd) 0.65 (0.7) 0.5 (0.7) 0.037 Range (median) 0-0.275 (0.375) 0-0.25 (0.125) Severity scale Late onset (138) Early onset(122) p 0-1 2-3-4 0-1 2-3-4 Heart 117 21 121 1 <0.0001 Kidney 138 0 117 5 0.02 Conclusion: Our study demonstrate that similarly to systemic lupus erithematosus and rheumatoid arthritis, distinct differences related to age at onset also occur in SSc patients. References: • Calvo-Alen J. et al, Clin Rheumatol 2005 • Lalani S. et al, J Rheumatol 2010 • Ho CT et al, Ann Rheum 1998 Disclosure of Interest: None declared Citation: Ann Rheum Dis 2010;69(Suppl3):247 Session: Scleroderma, Myositis and related syndromes

2010 Cuomo, Giovanna; Iudici, M.; Abignano, G.; Valentini, G.

[OP0219] EUROPEAN SCLERODERMA STUDY GROUP (ESCSG) ACTIVITY INDEX IS CORRELATED TO QUALITY OF LIFE MEASURES BOTH AT ADMISSION AND OVERTIME M. Iudici, G. Cuomo, G. Abignano, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Objectives: EScSG activity index has been validated for construct validity [1]. Its discriminant validity awaits to be investigated. In order to address this aspect, we investigated the relationship between the activity index and Health Assessment Questionnaire-Disability Index, physical and mental component scores (PCS and MCS) of Short Form-36 (SF36). Methods: 140 SSc patients consecutively admitted at tertiary center were investigated for EScSG activity index, HAQ-DI and PCS and MCS of SF36 at enrolment and after 1 year. The change (Δ) for each of the all measures was calculated. Results: EScSG activity index was found to be correlated to HAQ-DI, PCS and MCS both at admission (Rho=0.49, p=0.0003; Rho= -0.40, p<0.0001; Rho= -0.29, p=0.001, respectively) and after 1 year (Rho=0,64, p<0,0001; Rho= -0.29, p=0.001; Rho=-0.18, p=0.046 respectively). Moreover, the change between the value of the activity index at 1 year and that at admission (Δ activity index) was significantly correlated to ΔHAQ-DI, ΔPCS, ΔMCS (Rho=0,43, p=0.002; Rho=0,56, p<0.0001; Rho=0.48, p=0.002, respectively). Conclusion: HAQ-DI and SF36 (PCS and MCS) are considered to be validated outcome measure in SSc. Our results further support the construct validity of EScSG activity index and are for the first time underline its discriminant validity. References: • Valentini G. et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003. Disclosure of Interest: None declared Citation: Ann Rheum Dis 2010;69(Suppl3):128 Session: Abstract Session: Modern prespective in systemic sclerosis

2010 Iudici, M.; Cuomo, Giovanna; Abignano, G.; Valentini, G.

CROSS-SECTIONAL EVALUATION OF CHEMOKINE PROFILE IN EARLY AND DEFINITE SYSTEMIC SCLEROSIS

2010 Vettori, Serena; Cuomo, Giovanna; Abignano, G.; Iudici, M.; D'Aiuto, E.; DE PALMA, Raffaele; Valentini, G.

THE PROLIFERATIVE TRANSCRIPTIONAL FACTORS FOXE3 IS THE TARGET OF ANTI-CENP-A ANTIBODIES (AB) AND IDENTIFIES A SUBSET OF ANTI-CENP AB POSITIVE SYSTEMIC SCLEROSIS PATIENTS

2010 Perosa, F.; Vicenti, C.; Racanelli, V.; Cuomo, Giovanna; Valentini, G.; Dammacco, F.

Titolo	Data di pubblicazione	Autore(i)
Dipeptidyl peptidase 4 inhibitor sitagliptin reduces oxidative stress, endothelial dysfunction and preserves diastolic function in a rat model of heart failure with preserved ejection fraction	1-gen-2016	Urbanek, K; Cappetta, D; Piegari, Elena; Esposito, G; Russo, R; Ciuffreda, Lp; Rivellino, A; Berrino, Liberato; Rossi, Francesco; DE ANGELIS, Antonella
Diurnal time course of sleepiness in Italian junior and high school students	1-gen-2016	Cerasuolo, M; Arzilli, C; Conte, F; Giganti, F; Ficca, Gianluca
A methodology to awake citizens' awareness on the effects of leisure noise	1-gen-2017	Maffei, Luigi; Masullo, Massimiliano; Ciaburro, Giuseppe; D'Onofrio, L.
A Unique Myopathy Syndrome in a Patient Disclosing Clinical, Laboratory, and Genetic Findings of Late-Onset Pompe Disease, Together with a Lack of Dysferlin on Muscle Biopsy	1-gen-2015	Sampaolo, Simone; Lombardi, Luca; Pascarella, Angelo; Picillo, Esther; Farina, Olimpia; Esposito, Teresa; Politano, Luisa; DI IORIO, Giuseppe
18. Imapired excerise performance in systemic sclerosis. Clinical correlations	1-gen-2008	Valentini, G.; Santoriello, C.; Cuomo, Giovanna; Polverino, F.; Ruocco, L.; Polverino, M. .
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes	1-gen-2009	Abignano, G.; Iudici, M.; Petrillo, A.; Cuomo, Giovanna; Valentini, Gabriele
TWENTYFOUR-MONTH AZATHIOPRINE AS MAINTENANCE THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE TREATED WITH LOW DOSE CYCLOPHOSPHAMIDE PULSE THERAPY	1-gen-2009	Abignano, G.; Cuomo, Giovanna; Iudici, M.; Petrillo, A.; Valentini, G.
[FRI0311] CORRELATIONS BETWEEN CLINICAL FEATURES OF154 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND SHORT FORM36 (SF36) SCORES G. Cuomo, M. Iudici, G. Abignano, A. Petrillo, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Background: The quality of life is reduced in patients with systemic sclerosis (SSc) as evaluated by both disease specific (HAQ-DI; SHAQ) or generic questionnaires. The correlations between SF-36 scores and some disease features have not yet been explored. Objectives: To evaluate the relationships between health values as evaluated by SF-36 and clinical features in SSc patients. Methods: From 9/01/07 to 8/31/08 154 consecutive SSc patients (144 females; 10 males); aged from 20–82 years (median age 54), with disease duration from 1-47 years (median 10,5 years); attending the outpatient clinic of the Rheumatology Unit of Second University of Naples, were enrolled in the study. The scores of the eight areas of SF-36 General Health: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social function (SF), Role Emotional (RE) and Mental Health (MH), were evaluated in the range of 0–100, the higher values reflecting a better Quality of life (Qol). In addition two global series i.e. the Physical Component Summary Score (PCS) and the Mental Component Summary Score (MCS) were calculated. The patients were also investigated for disease subset (limited or diffuse); skin involvement by the modified Rodnan skin score; disability by HAQ-DI; disease activity by European Activity Index, and disease severity by Medsger severity scale. Results: SF36 score did not differ between the 31 patients with diffuse vs the 123 with limited disease All the items of SF36 were significantly correlated to activity Index (Rho from –0.28 to -0.32: p<0.0001) and HAQ-DI (Rho from -0.38 to -0.82: p<0.0001). GH resulted to correlate with mRss (Rho -0.17; p<0.05) The significant correlations between each item of the Medsger's severity scale and each item of SF36 are reported in table. PF RP BP GH VT SF RE MH PCS/MCS Sev_Gen (Rho) – – – – – – – – –/– Sev_Vasc(Rho) – – – – – – – – –/– Sev_Skin (Rho) – – – – – – – – –/– Sev_Joint (Rho) – – – -0.18* – – – – -0.21/– Sev_muscle (Rho) -0.25 – – -0.16* -0.18* -0.22* – -0.20* -0.20/– Sev_GI (Rho) -0.20 – – -0.22 – – – – –/– Sev_lung (Rho) -0.28* – – -0.23** -0.17* -0.23 -0.22 – -0.19/– Sev_Heart (Rho) – – -0.22 – – – – – -0.21/– Sev_kidney (Rho) – – – – – – – – – p<0.05; p<0.001; *p<0.0001. Conclusion: The present study, confirms that the Health Value, as evaluated by SF36, is diminished in SSc. Our study point out a previously univestigated correlation between SF-36 scores and disease activity. Disclosure of Interest: NONE declared Ann Rheum Dis 2009;68(Suppl3):459 Session: Scleroderma, myositis and related syndromes	1-gen-2009	Cuomo, Giovanna; Iudici, M.; Abignano, G.; Petrillo, A.; Valentini, G.
MYCOPHENOLATE MOFETIL IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS	1-gen-2009	Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G. .
AUTOANTIBODIES AND CLINICAL FEATURES CAN PREDICT EVOLUTION IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE (MCTD)	1-gen-2011	Cappelli, S.; Bellando Randone, S.; Martinovic, D.; Tamas, M. M.; Pasalic, K.; Allanore, Y.; Mosca, M.; Talarico, R.; Opris, D.; Kiss, C.; Tausche, A. K.; Cardarelli, S.; Riccieri, V.; Koneva, O.; Cuomo, Giovanna; Becker, M. O.; Sulli, A.; Guiducci, S.; Radic, M.; Bombardieri, S.; Aringer, M.; Cozzi, F.; Valesini, G.; Ananieva, L.; Valentini, G.; Riemekasten, G.; Cutolo, M.; Ionescu, R.; Czirják, L.; Damjanov, N.; Rednic, S.; Matucci Cerinic, M.
ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC). ULTRASONOGRAPHIC FEATURES OF HAND JOINTS	1-gen-2009	Cuomo, Giovanna; Zappia, M.; Abignano, G.; Petrillo, A.; Iudici, M.; Valentini, G.
THE ROLE OF HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) IN PREDICTING SURVIVAL IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC)	1-gen-2011	Iudici, M.; Cuomo, Giovanna; D'Abrosca, V.; Irace, R.; Valentini, G.
COURSE OF HBV INFECTION IN PATIENTS UNDERGOING TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)	1-gen-2011	Urraro, T.; Cuomo, Giovanna; Valentini, G.
HYPOCOMPLEMENTEMIA IN SYSTEMIC SCLEROSIS (SSC)	1-gen-2008	Cuomo, Giovanna; Abignano, G.; Petrillo, A.; Valentini, G.
CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS	1-gen-2007	Vettori, Serena; Abbadessa, Salvatore; Chiarolanza, I.; Ruocco, L.; Cuomo, Giovanna; Maresca, L.; Leonardo, G.; Valentini, G.
ELF TEST: A PROMISING SURROGATE OUTCOME MEASURE IN SYSTEMIC SCLEROSIS	1-gen-2011	G., Abignano; Cuomo, Giovanna; Buch, M.; Rosenberg, W. M.; Valentini, G.; Emery, P.
[THU0309] CLINICAL MANIFESTATIONS IN LATE VS EARLY –ONSET SYSTEMIC SCLEROSIS (SSC) G. Cuomo, M. Iudici, G. Abignano, G. Valentini. Second Universty of Naples, Rheumatology Unit, Naples, Italy Background: Differences have been so far pointed out in the clinical manifestations and disease course in patients with a number of autoimmune rheumatic diseases and different age at onset (1-3). Objectives: To investigate the occurrence of differences between early and late onset SSc. Methods: 260 SSc patients (233 females) with a median age at the onset of the disease of 40.5 years (range 8-74) were consecutively admitted to a tertiary centre from November 1st 2000 to October 31st 2008. They were divided into 2 groups: early onset (<40.5 years) and late onset (≥40.5 years). Differences in each of the epidemiological, clinical and serological aspects collected in all the patients at admission were analysed. Results: Table 1 lists the significant differences detected between the 2 groups. Early onset patients were found to have a longer disease duration at presentation, a higher prevalence of anti-Scl70 positivity and a higher prevalence of scleroderma renal crisis; a lower prevalence of antinucleolar antibody positivity; a lower percentage of pulmonary hypertension; a lower HAQ-DI and a lower prevalence of heart involvement. No difference was detected in clinical subset distribution. Late onset (138) Early onset (122) p Disease duration mean (sd) 6 (6) 10 (10) 0.003 Range (median) 0.5-26 (5) 0.5-45 (6) Serological subset Scl70 43 54 0.04 Nucleolar 9 23 0.004 PAPs ≥40mmHG (echocardiography) 14/124 3/119 0.01 HAQ-DI mean (sd) 0.65 (0.7) 0.5 (0.7) 0.037 Range (median) 0-0.275 (0.375) 0-0.25 (0.125) Severity scale Late onset (138) Early onset(122) p 0-1 2-3-4 0-1 2-3-4 Heart 117 21 121 1 <0.0001 Kidney 138 0 117 5 0.02 Conclusion: Our study demonstrate that similarly to systemic lupus erithematosus and rheumatoid arthritis, distinct differences related to age at onset also occur in SSc patients. References: • Calvo-Alen J. et al, Clin Rheumatol 2005 • Lalani S. et al, J Rheumatol 2010 • Ho CT et al, Ann Rheum 1998 Disclosure of Interest: None declared Citation: Ann Rheum Dis 2010;69(Suppl3):247 Session: Scleroderma, Myositis and related syndromes	1-gen-2010	Cuomo, Giovanna; Iudici, M.; Abignano, G.; Valentini, G.
[OP0219] EUROPEAN SCLERODERMA STUDY GROUP (ESCSG) ACTIVITY INDEX IS CORRELATED TO QUALITY OF LIFE MEASURES BOTH AT ADMISSION AND OVERTIME M. Iudici, G. Cuomo, G. Abignano, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Objectives: EScSG activity index has been validated for construct validity [1]. Its discriminant validity awaits to be investigated. In order to address this aspect, we investigated the relationship between the activity index and Health Assessment Questionnaire-Disability Index, physical and mental component scores (PCS and MCS) of Short Form-36 (SF36). Methods: 140 SSc patients consecutively admitted at tertiary center were investigated for EScSG activity index, HAQ-DI and PCS and MCS of SF36 at enrolment and after 1 year. The change (Δ) for each of the all measures was calculated. Results: EScSG activity index was found to be correlated to HAQ-DI, PCS and MCS both at admission (Rho=0.49, p=0.0003; Rho= -0.40, p<0.0001; Rho= -0.29, p=0.001, respectively) and after 1 year (Rho=0,64, p<0,0001; Rho= -0.29, p=0.001; Rho=-0.18, p=0.046 respectively). Moreover, the change between the value of the activity index at 1 year and that at admission (Δ activity index) was significantly correlated to ΔHAQ-DI, ΔPCS, ΔMCS (Rho=0,43, p=0.002; Rho=0,56, p<0.0001; Rho=0.48, p=0.002, respectively). Conclusion: HAQ-DI and SF36 (PCS and MCS) are considered to be validated outcome measure in SSc. Our results further support the construct validity of EScSG activity index and are for the first time underline its discriminant validity. References: • Valentini G. et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003. Disclosure of Interest: None declared Citation: Ann Rheum Dis 2010;69(Suppl3):128 Session: Abstract Session: Modern prespective in systemic sclerosis	1-gen-2010	Iudici, M.; Cuomo, Giovanna; Abignano, G.; Valentini, G.
CROSS-SECTIONAL EVALUATION OF CHEMOKINE PROFILE IN EARLY AND DEFINITE SYSTEMIC SCLEROSIS	1-gen-2010	Vettori, Serena; Cuomo, Giovanna; Abignano, G.; Iudici, M.; D'Aiuto, E.; DE PALMA, Raffaele; Valentini, G.
THE PROLIFERATIVE TRANSCRIPTIONAL FACTORS FOXE3 IS THE TARGET OF ANTI-CENP-A ANTIBODIES (AB) AND IDENTIFIES A SUBSET OF ANTI-CENP AB POSITIVE SYSTEMIC SCLEROSIS PATIENTS	1-gen-2010	Perosa, F.; Vicenti, C.; Racanelli, V.; Cuomo, Giovanna; Valentini, G.; Dammacco, F.

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 641 a 660 di 2.295

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext2294
open1